The clinical neuroimmunotherapeutic role of melatonin in oncology: Mini Review

Journal of Pineal Research

Volumn 19, Issue 3, 1995, Pages 103-110

  Conti, Ario ^a   Maestroni, Georges J M ^a  

^a INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

cancer immunotherapy; interleukin 2; Melatonin

Indexed keywords

INTERLEUKIN 1; MELATONIN;

ANIMAL; DRUG COMBINATION; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; NEOPLASM; PHYSIOLOGY; PINEAL BODY; REVIEW;

ANIMALS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-1; MELATONIN; NEOPLASMS; NEUROIMMUNOMODULATION; PINEAL GLAND;

EID: 0029384970     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.1995.tb00177.x     Document Type: Article

References (38)

1. Low‐dose interleukin‐2 subcutaneous immunotherapy in association with the pineal neurohormone melatonin as a first‐line therapy in locally advanced or metastatic hepatocellular carcinoma
2. Protective effects of melatonin in mice infected with encephalitis viruses
3. Immunoregulatory feed‐back between interleukin‐1 and glucocorticoid hormones
4. Relationhips between neuroendocrine hormones and lymphokines
5. Melatonin as immunomodulator in immunodeficient mice
6. Sympathetic nervous system and macrophage function. In: Ontogenic and phylogenetic mechanisms of neu‐roimmunomodulation
7. Melatonin‐induced‐immuno‐opioids: role in lymphoproliferative and autoimmune diseases
8. Pinealectomy inhibits interleukin‐2 production and natural killer activity in mice
9. Medical treatment and long‐term survival in a prospective study of 84 patients with endocrine pancreas tumors
10. Melatonin biosynthesis and metabolism in peripheral blood mononuclear leucocytes
11. Interferon‐alpha 2 enhances slow‐wave sleep in rabbits
12. Sleep promoting effects of endogenous pyrogen (interleukin‐1)
13. Amplification of eosinophilia by melatonin during the immunotherapy of cancer with interleukin‐2
14. Immunological effects of a single evening subcutaneous injection of low‐dose interleukin‐2 in association with the pineal hormone melatonin in advanced cancer patients
15. Endocrine and immune effects of melatonin therapy in metastatic cancer patients
16. The pineal hormone melatonin as a second line therapy in metastic non‐small‐cell lung cancer resistant to chemotherapy
17. A randomized study with subcutaneous low dose interleukin 2 alone vs interleukin 2 plus melatonin in advanced solid neoplasms other than renal cancer and melanoma
18. Immunoendocrine therapy with low‐dose subcutaneous interleukin‐2 plus melatonin of locally advanced or metastatic endocrine tumors
19. Biological and clinical results of a neuroimmunotherapy with interleukin‐2 and the pineal hormone melatonin as a first line treatment in advanced non‐small‐cell lung cancer
20. Neuroimmunoterapia dei tumori solidi avanzati con interleuchina 2 e melatonina: studi di fase 2 (200 casi) e fase 3
21. Effect of adrenergic agents on hematopoiesis after syngeneic bone marrow transplantation in mice
22. Noradrenergic modulation of lymphohematopoiesis
23. Modulation of hematopoiesis via a‐1‐adrenergic receptors on bone marrow cells
24. The immunoneuroendocrine role of melatonin
25. T‐helper‐2 lymphocytes as a peripheral target of melatonin
26. + cells to release opioid agonist(s) with immunoenhancing and anti‐stress properties
27. Anti‐stress role of the melatonin‐immuno‐opioid network. Evidence for a physiological mechanism involving T cell‐derived, immunoreactive pendorphin and metenkephalin binding to thymic opioid receptors
28. Melatonin in relation to the immune system
29. Haematopoietic rescue via T‐cell‐dependent, endogenous granulocyte‐macrophage colony‐stimulating factor induced by the pineal neurohormone melatonin in tumor bearing mice
30. Colony‐stimulating activity and haematopoietic rescue from cancer chemotherapy compounds are induced by melatonin via endogenous interleukin‐4
31. Activation of human monocytes by the pineal neurohormone melatonin
32. Treatment of malignant carcinoid tumors: a randomized controlled study of streptozotocyn plus 5‐FU and human leukocyte interferon
33. Melatonin increases antigen presentation and amplifies specific and nonspecific signals for T‐cell proliferation
34. A review of the evidence supporting melatonin's role as antioxydant
35. Thymic neuropeptides and T‐lym‐phocyte development. In: Ontogenic and phylogenetic mechanisms of neuroimmunomodulation
36. Preliminary studies on melatonin in the treatment of myelodysplastic syndromes following cancer chemotherapy